News-Medical.Net on MSN

CRISPR-based Cellgorithm technology ushers in a new era of cell programming

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...
Nasdaq

Intellia Therapeutics Presents New Preclinical Data Showing Persistent In Vivo Editing and Durability of Effect Following CRISPR/Cas9-Based Treatment

In Vivo gene knockout and insertion data to be presented at OTS Annual Meeting highlight modularity of Intellia’s platform and potential for variety of single-course therapies, with company’s first ...
The American Journal of Managed Care

Making the Genetic Models Match the Ancestry of Patient Populations

The problem, Zaaijer explained, is that algorithms used in precision medicine models overwhelming are built on DNA with ...
News Medical

CRISPR-GPT helps scientists to generate designs, analyze data and troubleshoot design flaws

Stanford Medicine researchers have developed an artificial intelligence tool to help scientists better plan gene-editing experiments. The technology, CRISPR-GPT, acts as a gene-editing "copilot" ...
Seeking Alpha

CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and ...

ZUG, Switzerland and BOSTON, Oct. 01, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, ...
TipRanks on MSN

CRISPR Therapeutics AG: Stock surge amid challenges

Crispr Therapeutics AG ( ($CRSP) ) has risen by 9.03%. Read on to learn why. Crispr Therapeutics AG has seen its stock price rise by 9.03% over ...

Bernstein Reaffirms Their Hold Rating on Crispr Therapeutics AG (CRSP)

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.